The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Will Be The Estimated Market Valuation Of The Inhaler Corticosteroid Device Market By The End Of 2030?
The inhaler corticosteroid device market has experienced substantial growth in its size over recent years. Projections indicate it will expand from $16.83 billion in 2025 to $17.98 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.8%. Key drivers behind this historical growth include an escalating prevalence of asthma and COPD, enhanced understanding of inhaler treatments, governmental programs supporting respiratory well-being, innovations in metered-dose inhalers, and the expansion of hospital and homecare infrastructure.
The inhaler corticosteroid device market is projected to experience substantial expansion over the upcoming years. Its value is anticipated to reach $23.18 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.6%. This growth during the projection period can be primarily ascribed to the incorporation of AI and IoT into inhaler technologies, the creation of environmentally friendly inhalers, the broader availability of telehealth services, tailored medication dispensing, and increasing consumption in developing economies. Key developments anticipated within this timeframe involve the integration of smart inhalers, customized dosage oversight, remote monitoring facilitated by telehealth, sustainable and eco-conscious device designs, and sophisticated aerosol delivery systems.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25794&type=smp
What Primary Drivers Are Shaping The Development Of The Inhaler Corticosteroid Device Market?
The rising incidence of respiratory diseases is anticipated to drive the expansion of the inhaler corticosteroid device market. Respiratory conditions encompass various ailments affecting the lungs and airways, impeding proper and efficient breathing. The growing occurrence of these diseases is attributed to increased air pollution, which exposes individuals to damaging particles that harm lung tissue and precipitate chronic conditions such as asthma and bronchitis. Inhaler corticosteroid devices are utilized to manage respiratory diseases by delivering anti-inflammatory medication directly into the lungs, thereby alleviating inflammation and enhancing breathing. For instance, in June 2025, data from the Office for Health Improvement and Disparities, a UK-based government department, indicated that England recorded 854,922 emergency hospital admissions for respiratory diseases in the financial year ending 2024. This figure corresponds to a rate of 1,428 (ranging from 1,424 to 1,432) per 100,000 population, representing a 7% increase compared to the previous year. Consequently, the escalating prevalence of respiratory diseases is fueling the growth of the inhaler corticosteroid device market.
Which Segment Classifications Shape The Inhaler Corticosteroid Device Market?
The inhaler corticosteroid device market covered in this report is segmented –
1) By Product Type: Metered-Dose Inhalers, Dry Powder Inhalers, Soft Mist Inhalers
2) By Formulation Type: Fluticasone Propionate, Budesonide, Beclomethasone, Mometasone Furoate
3) By Distribution Channel: Online Pharmacies, Retail Pharmacies, Direct Sales, Hospital Pharmacies
4) By Application: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Other Applications
5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Metered-Dose Inhalers: Conventional Metered-Dose Inhalers, Breath-Actuated Metered-Dose Inhalers, Spacer-Integrated Metered-Dose Inhalers
2) By Dry Powder Inhalers: Single-Dose Dry Powder Inhalers, Multi-Dose Dry Powder Inhalers, Reservoir Dry Powder Inhalers
3) By Soft Mist Inhalers: Manual Soft Mist Inhalers, Battery-Operated Soft Mist Inhalers
How Are Trends Impacting The Inhaler Corticosteroid Device Market?
Major companies operating in the inhaler corticosteroid device market are prioritizing the introduction of innovative solutions, including rescue inhalers that combine albuterol and budesonide. This focus is aimed at enhancing treatment effectiveness and offering patients a more convenient, dual-action therapy from a single device. An inhaler that integrates albuterol and budesonide provides a dual-action rescue capability, delivering both a bronchodilator (albuterol) to quickly open airways and a corticosteroid (budesonide) to reduce inflammation, thereby offering prompt symptom relief and long-term asthma control in one device. As an illustration, in January 2024, AstraZeneca PLC, a UK-based pharmaceutical industry company, launched AIRSUPRA. This product is notable as the first and only FDA-approved rescue inhaler to combine albuterol and budesonide for adults with asthma. Its design allows for as-needed use to both alleviate acute bronchoconstriction symptoms and diminish airway inflammation, which in turn lowers the risk of severe asthma exacerbations. This represents a novel strategy by combining a short-acting beta2-agonist (albuterol) with an inhaled corticosteroid (budesonide) in a single inhaler, approved based on clinical trials that demonstrated its superior effectiveness over albuterol alone in preventing asthma attacks.
Which Companies Are Expanding Their Footprint In The Inhaler Corticosteroid Device Market?
Major companies operating in the inhaler corticosteroid device market are AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Teijin Pharma Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Chiesi Farmaceutici S.p.A., Cipla Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Mundipharma International Limited, Lupin Limited, Zydus Lifesciences Limited, Recipharm AB, Glenmark Pharmaceuticals Limited, Orion Corporation, Beximco Pharmaceuticals Limited, PARI Medical Holding GmbH
Read the full inhaler corticosteroid device market report here:
https://www.thebusinessresearchcompany.com/report/inhaler-corticosteroid-device-global-market-report
How Does The Inhaler Corticosteroid Device Market Perform Across Major Global Regions?
North America was the largest region in the inhaler corticosteroid device market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inhaler corticosteroid device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Inhaler Corticosteroid Device Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=25794&type=smp
Browse Through More Reports Similar to the Global Inhaler Corticosteroid Device Market 2026, By The Business Research Company
Implantable Infusion Pumps Market Report 2026
https://www.thebusinessresearchcompany.com/report/implantable-infusion-pumps-global-market-report
Intravenous Infusion Pumps Market Report 2026
https://www.thebusinessresearchcompany.com/report/intravenous-infusion-pumps-global-market-report
Ambulatory Iv Infusion Pumps Market Report 2026
https://www.thebusinessresearchcompany.com/report/ambulatory-iv-infusion-pumps-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model